Mode
Text Size
Log in / Sign up

Systematic review and meta-analysis of creatine in postmenopausal women finds lean mass and strength benefits

Systematic review and meta-analysis of creatine in postmenopausal women finds lean mass and…
Photo by Andrey Khoviakov / Unsplash
Key Takeaway
Consider creatine may modestly increase lean mass and strength in postmenopausal women, but bone effects remain uncertain.

This is a systematic review and meta-analysis of randomized trials examining creatine monohydrate supplementation in postmenopausal women aged 40 to 45 years and older. The review synthesized evidence from 608 randomized participants, with follow-up ranging from 12 to 104 weeks (median 38 weeks). The intervention was creatine monohydrate, with or without resistance training, compared to placebo.

The authors found a mean difference of +0.37 kg for DXA-derived lean mass (95% CI +0.05 to +0.69; k=5; n=338) and a mean difference of +7.5 kg for leg-press one-repetition maximum strength (95% CI +2.2 to +12.8; k=3; n=111), both favoring creatine. Bone mineral density was reported as unchanged overall. Safety outcomes indicated mild adverse events similar to placebo, with renal indices unchanged.

Limitations noted by the authors include mostly some concerns regarding risk of bias, though one large, preregistered, double-blind RCT was at low risk. The review itself was not prospectively registered. GRADE certainty was assessed, and effects on bone density remain unclear.

Practice relevance was not reported. The findings suggest potential benefits for lean mass and strength, but the evidence is not definitive and should be considered in the context of these limitations.

Study Details

Study typeMeta analysis
EvidenceLevel 1
Follow-up540.0 mo
PublishedDec 2026
View Original Abstract ↓
BACKGROUND: Menopause is accompanied by accelerated losses in muscle mass and strength and declining bone density. Whether creatine monohydrate benefits postmenopausal women are uncertain. METHODS: We systematically reviewed randomized, placebo-controlled trials examining creatine supplementation, with or without resistance training (RT), in postmenopausal women. MEDLINE, Embase, Scopus, Web of Science, SPORTDiscus, and Cochrane CENTRAL were searched from 2000 to August 2025, supplemented by trial registries and reference-list screening. Eligible studies included postmenopausal women aged ≥40-45 years, intervention durations ≥6 weeks for primary analyses, and outcomes including DXA-derived lean mass, one-repetition maximum (1RM) strength, bone mineral density, physical function, and safety. Dual screening, duplicate extraction, and Cochrane RoB 2 assessment were performed. Random-effects meta-analysis used the Paule-Mandel estimator for τ² with Hartung-Knapp-Sidik-Jonkman adjustment. Heterogeneity (τ², I²), 95% prediction intervals, subgroup analyses by RT status, exploratory dose/duration meta-regression, small-study effects, and GRADE certainty were assessed. RESULTS: Seven RCTs ( = 608 randomized; duration 12-104 weeks, median 38 weeks) enrolled postmenopausal women (mean age ≈ 62 y). Lean mass (k = 5;  = 338) favored creatine: mean difference (MD) + 0.37 kg (95% CI + 0.05 to + 0.69; I² = 25%; τ² = 0.01; 95% PI -0.10 to + 0.84). Leg-press 1RM (k = 3;  = 111) improved with creatine: MD + 7.5 kg (95% CI + 2.2 to + 12.8; I² = 0%). Benefits were evident when creatine ≥ 5 g·day⁻¹ was combined with RT; trials using ≤ 3 g·day⁻¹ without RT showed no measurable effect. Bone density was unchanged overall. Adverse events were mild and similar to placebo; renal indices were unchanged. Risk of bias was mostly "some concerns;" one large, preregistered, double-blind RCT was at low risk. CONCLUSIONS: In postmenopausal women, creatine, particularly ≥ 5 g·day⁻¹ with RT, yields small but meaningful gains in lean mass and strength without evidence of harm. Effects on bone density remain unclear.Registration: This review was not prospectively registered. De-identified data and supplementary materials were deposited on OSF after completion of the analysis (DOI: 10.17605/OSF.IO/BVTRZ).
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.